Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results from MZL cohort of TRANSCEND FL presented at ICML in ...
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has granted approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult ...
Breyanzi is a cell-based immunotherapy approved for treating certain kinds of B-cell lymphoma in adults. It’s used in situations where cancer has come back after past treatment or is not responding to ...
With Bristol Myers Squibb only a month away from biopharma's biggest loss of exclusivity this year, industry watchers are eager for any clues about how the company's new and future medicines will ...
With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
Breyanzi showed significant efficacy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma, achieving primary and secondary endpoints in the TRANSCEND FL trial. Marginal zone lymphoma, a slow ...
The cost of Breyanzi can vary based on several factors such as your insurance coverage. A program called Cell Therapy 360 may be able to help lower the price you’ll pay for this treatment. To find out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results